Pfizer Shares Plunge 2.02% Amid Vaccine Advances and Cancer Deal, Ranked 118th in $860M Trading Volume

On July 30, 2025, Pfizer (PFE) declined by 2.02% with a trading volume of $0.86 billion, ranking 118th in market activity. Recent developments include the completion of a large-scale study evaluating the effectiveness of its Pfizer-BioNTech COVID-19 vaccine in preventing hospitalizations, which could reinforce investor confidence in its vaccine portfolio. Additionally, the European Commission is expected to authorize the LP.8.1-adapted vaccine formulation, designed to target emerging variants such as XFG and NB.1.8.1, following a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Pfizer also finalized a licensing agreement with 3SBio for an investigational cancer immunotherapy, expanding its oncology pipeline. The deal complements its existing portfolio and aligns with its strategy to enhance long-term growth through innovative therapies. While the company’s recent stock performance reflects short-term volatility, ongoing data from clinical trials and regulatory advancements in key therapeutic areas, including vaccines and oncology, position it to address evolving market demands.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark’s 29.18%. This approach leverages short-term momentum in high-volume stocks, capturing price movements driven by sustained investor interest and market activity. The consistent performance across multiple equities highlights the effectiveness of volume-based strategies in volatile markets.